| Literature DB >> 24291476 |
Kuan-Nien Chou1, Yu-chieh Lin2, Ming-Ying Liu1, Ping-Ying Chang3.
Abstract
Temozolomide (TMZ), an alkylating agent, is widely used for treating high-grade gliomas. TMZ has been reported to cause secondary myelodysplastic syndrome and acute myeloid leukemia. However, TMZ-related acute lymphoblastic leukemia is rare. Here we describe a 54-year-old woman with glioblastoma multiforme, who developed precursor-B acute lymphoblastic leukemia with translocation (4;11)(q21;q23) after 15 months of TMZ treatment.Entities:
Keywords: Glioblastoma multiforme; Secondary acute lymphoblastic leukemia; Temozolomide; Therapy-related acute lymphoblastic leukemia
Mesh：
Substances：
Year: 2013 PMID： 24291476 DOI： 10.1016/j.jocn.2013.07.032
Source DB: PubMed Journal: J Clin Neurosci ISSN： 0967-5868 Impact factor: 1.961